SavedAdd your journal

Journals / Viral Hepatitis Journal / 2019 / Cilt: 25 - Sayı: 1

Sixteen-year Prognosis of Treatment-naive Patients with Hepatitis C Infection

Naiv Hepatit C Enfeksiyonlu Hastaların On-altı Yıllık Prognozu

Selma TOSUN
Seher Ayten ÇOŞKUNER
Mustafa DOĞAN
Büşra ERGÜT SEZER
Emre GÜVEN
Neslihan ÇELİK
Pınar ERGEN
Uğur KOSTAKOĞLU
Ramazan GÖZÜKÜÇÜK
Zehra KARACAER
Nefise ÖZTOPRAK
Mustafa UĞUZ
Ayşe BATIREL
Muhammed BEKÇİBAŞI
Gül DURMUŞ
İlknur ESEN YILDIZ
Ali ACAR
Özlem AYDIN
Ercan YENİLMEZ
Cu
Pages
19–24
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

During the follow-up period, the final values of alanine aminotransferase, aspartate transaminase, and total protein were significantly decreased when compared to the initial values (p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objectives: In this study, we aimed to evaluate the clinical course of treatment-naive patients infected with hepatitis C virus (HCV) who were followed up in various centers in Turkey.
📊
Key Findings & Data:Materials and Methods: This was a retrospective study performed with the participation of 15 centers.
💡
Conclusion & Impact:During the follow-up period, the final values of alanine aminotransferase, aspartate transaminase, and total protein were significantly decreased when compared to the initial values (p
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objectives: In this study, we aimed to evaluate the clinical course of treatment-naive patients infected with hepatitis C virus (HCV) who were followed up in various centers in Turkey. Materials and Methods: This was a retrospective study performed with the participation of 15 centers. Patients aged 18 years and older with HCV infection were included. Results: A total of 391 treatment-naive patients infected with HCV were included in this study. During the follow-up period, the final values of alanine aminotransferase, aspartate transaminase, and total protein were significantly decreased when compared to the initial values (p

Özet

Amaç: Bu çalışmada ülkemizin çeşitli merkezlerinde takip edilen naiv hepatit C virüs (HCV) ile enfekte hastaların klinik seyrini değerlendirmeyi amaçladık. Gereç ve Yöntemler: Bu çalışma retrospektif olarak 15 merkezin katılımıyla gerçekleştirilmiştir. Çalışmaya 18 yaş üstü, HCV enfeksiyonu olan hastalar dahil edilmiştir. Bulgular: Çalışmada 391 tedavi-naiv HCV enfeksiyonlu hasta yer almıştır. Hastaların takip süresinde son alanine aminotransferase, aspartate transaminase ve total protein değerleri ilk düzeyine göre önemli düzeyde azalmıştır (sırasıyla p

🔖

Cite This Article

TOSUN, S., ÇOŞKUNER, S. A., DOĞAN, M., SEZER, B. E., GÜVEN, E., ÇELİK, N., ERGEN, P., KOSTAKOĞLU, U., GÖZÜKÜÇÜK, R., KARACAER, Z., ÖZTOPRAK, N., UĞUZ, M., BATIREL, A., BEKÇİBAŞI, M., DURMUŞ, G., YILDIZ, İ. E., ACAR, A., AYDIN, Ö., YENİLMEZ, E., Cu, C. (2022). Sixteen-year Prognosis of Treatment-naive Patients with Hepatitis C Infection. Viral Hepatitis Journal, Cilt: 25 - Sayı: 1, 19–24. https://ajindex.com/articles/646371

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (11)

  1. World Health Organization. Global report on access to hepatitis C treatment, 2016 (cited 2017 Feb 20). Available from: http://www. who.int/hepatitis/publications/hep-c-access-report/en/
  2. Irving WL, Salmon D, Boucher C, Hoepelman IM. Acute hepatitis C virus infection. Euro Surveill. 2008:13
  3. World Health Organization. Guidelines for the screening, care and treatment of persons with hepatitis C infection, 2014 (cited 2017 Feb 20). Available from: http://www.who.int/hiv/pub/hepatitis/ hepatitis-c-guidelines/en/ 4. Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol. 2006;45:529-538
  4. Alacacioglu A, Somali I, Simsek I, Astarcioglu I, Ozkan M, Camci C, Alkis N, Karaoglu A, Tarhan O, Unek T, Yilmaz U. Epidemiology and survival of hepatocellular carcinoma in Turkey: Outcome of multicenter study. Jpn J Clin Oncol. 2008;38:683-688
  5. AASLD/IDSA HCV Guidance Panel. Hepatitis C guidance: AASLDIDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Hepatology. 2015;62:932-947
  6. Gebo KA, Herlong HF, Torbenson MS, Jenckes MW, Chander G, Ghanem KG; El-Kamari SS, Sulkowski M, Bass EB. Role of liver biopsy in management of chronic hepatitis C: a systematic review. Hepatology. 2002;36:161-172
  7. European Association for the study of the liver. Electronic address: [email protected]. EASL Recommendations on treatment of hepatitis C 2016. J Hepatol. 2017;66:153-194
  8. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet. 1997;349:825832
  9. Seeff LB. Natural history of chronic hepatitis C. Hepatology. 2002;36(5 Suppl 1):35-46
  10. Morgan TR, Ghany MG, Kim HY, Snow KK, Shiffman ML, De Santo JL, Lee WM, Di Bisceglie AM, Bonkovsky HL, Dienstag JL, Morishima C, Lindsay KL, Lok AS; HALT-C Trial Group. Outcome of sustained virological responders with histologically advanced chronic hepatitis C. Hepatology. 2010;52:833-844
  11. Van der Meer AJ, Veldt BJ, Feld JJ, Wedemeyer H, Dufour JF, Lammert F, Duarte-Rojo A, Heathcote EJ, Manns MP, Kuske L, Zeuzem S, Hofmann WP, de Knegt RJ, Hansen BE, Janssen HL. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA. 2012;308:2584-25